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Abstract
Background: The methods most commonly used to measure malarial antibody titres are the Indirect
Fluorescence Antibody Test (IFAT), regarded as the gold standard, and the Enzyme-Linked
ImmunoSorbent Assay (ELISA). The objective here was to assess the diagnostic performance, i.e. the
sensitivity and specificity, of a new malaria antibody ELISA kit in comparison to IFAT. This new ELISA kit,
the ELISA malaria antibody test (DiaMed), uses a combination of crude soluble Plasmodium falciparum
extract and recombinant Plasmodium vivax antigens.
Methods: Two groups were used: 95 samples from malaria patients to assess the clinical sensitivity and
2,152 samples from blood donors, who had not been exposed to malaria, to assess the clinical specificity.
Results: The DiaMed ELISA test kit had a clinical sensitivity of 84.2% and a clinical specificity of 99.6% as
compared with 70.5% and 99.6% respectively, using the IFAT method. The ELISA method was more
sensitive than the IFAT method for P. vivax infections (75% vs. 25%). However, in 923 malaria risk donors
the analytical sensitivity of the ELISA test was 40% and its specificity 98.3%, performances impaired by large
numbers of equivocal results non-concordant between ELISA and IFAT. When the overall analytical
performances of ELISA was compared to IFAT, the ELISA efficiency J index was 0.84 versus 0.71 for IFAT.
Overall analytical sensitivity was 93.1% and the analytical specificity 96.7%. Overall agreement between the
two methods reached 0.97 with a reliability k index of 0.64.
Conclusion: The DiaMed ELISA test kit shows a good correlation with IFAT for analytical and clinical
parameters. It may be an interesting method to replace the IFAT especially in blood banks, but further
extensive investigations are needed to examine the analytical performance of the assay, especially in a
blood bank setting.
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Background
More than 2 billion people (40% of the world's popula-
tion) live in areas where malaria is endemic. It was esti-
mated that over 250 million people worldwide contracted
malaria in 2002 [1]. Following infection with any of the
four species of Plasmodium, specific antibodies are pro-
duced, in virtually all individuals, one or two weeks after
initial infection and persist for three to six months after
parasite clearance. These antibodies may persist for
months or years in semi-immune patients in endemic
countries where reinfection is frequent. However, in a
non-immune patient, treated for a single infection, anti-
body levels fall more rapidly and may be undetectable by
three to six months. Reinfection or relapse leads to a sec-
ondary response with a high and rapid rise in antibody
titres [2,3]. Antibody detection is definitely not a substi-
tute for blood film examination in the diagnosis of an
acute attack of malaria, and is mainly used in screening of
prospective blood donors to avoid transfusion-transmit-
ted malaria [4,5]. Nowadays, that risk is still high due to
the extensive exchanges between malaria endemic areas
and non-endemic areas [4,6]. Malaria occurring in travel-
lers to the tropics is mainly due to Plasmodium falciparum
(60%) and Plasmodium vivax (24%) [7]. Anti-malarial
antibodies can be detected by various methods, which are,
however, believed to lack both sensitivity and specificity
[8]. Immuno-Fluorescence Antibody Test (IFAT) is still
regarded as the gold standard for malarial serology and
until recently was the only validated method for detecting
Plasmodium-specific antibodies in blood banks [9]. IFAT is
a simple and sensitive method, but it is time-consuming
and difficult to automate. It requires fluorescence micros-
copy and trained technicians, making it operator-depend-
ent and subjective, particularly for serum samples with
low antibody titres. Additionally, the lack of standardiza-
tion of IFAT reagents and manipulations makes it impos-
sible to harmonize inter-laboratory results. Moreover, the
antigen is obtained by in vitro culture of P. falciparum and
gives very good sensitivity for this species, but shows lim-
ited cross reactivity with other human pathogenic species.
An interesting solution would be to add an IFAT tech-
nique with Plasmodium cynomolgi antigens to detect anti-P.
vivax antibodies, but this would be impossible to apply
routinely in blood transfusion centres [10,11]. More
reproducible and easy to automate, ELISA methods, using
crude soluble antigen, lack sensitivity compared to IFAT
[12-14] but the more recent arrival of enzyme immu-
noassays using recombinant antigens [15] has provided a
more sensitive and practical alternative to IFAT.
Here a new ELISA kit (ELISA malaria antibody test,
DiaMed, Switzerland) was evaluated, which combines
soluble P. falciparum antigens and recombinant P. vivax
antigens and detects both IgG and IgM. This kit was com-
pared with the IFAT method routinely used. First, the sen-
sitivity of the two methods was determined with samples
from patients with clinical signs of malaria, using direct
examination as the reference method, in the knowledge
that anti-malarial antibodies are produced virtually in all
subjects one or two weeks after initial infection with all
four species and persist for 3–6 months after parasite
clearance [13,16]. Then the specificity of the two methods
was determined by testing a panel of sera from blood
donors not exposed to malaria and from malaria-risk
donors.
Materials and methods
Samples from Plasmodium infected patients
Sera from 95 patients were used to compare the perform-
ance of ELISA and IFAT. Seventy-six patients had returned
with fever from an endemic country and were microscop-
ically diagnosed positive for P. falciparum (n = 66), P. vivax
(n = 5), Plasmodium ovale (n = 2), Plasmodium malariae (n
= 2), or mixed P. falciparum and P. malariae infection (n =
1). These patients completed a questionnaire on endemic
zones visited and were divided into two categories: i)
patients returning from their first trip to a malaria-
endemic area and considered as having a primary infec-
tion (n = 32), and ii) patients having visited endemic areas
several times and considered as frequent tropical travellers
and possibly reinfected (n = 44). Nineteen patients were
infected by P. vivax in Venezuela and were considered as
residents (sera kindly provided by Dr. Hilda A. Perez, Lab-
oratorio de Immunoparasitologia of the Venezuelan Insti-
tute of Scientific Research, Caracas, Venezuela). These
samples were used to calculate the clinical sensitivity.
Samples from blood donors
Sera from blood donors were collected at Etablissement
Français du Sang d'Alsace (EFS Alsace). On the basis of a
medical questionnaire, donors were selected and classi-
fied as "not-exposed-to-malaria blood donors" (2152
sera) if they had not travelled to malarial endemic areas in
the last three years, the group that was used for the calcu-
lation of the clinical specificity, and as "malaria-risk blood
donors" (923 sera) if they had returned from a malarial
endemic area between the last four months to three years.
This last group of malaria-risk blood donors was used to
calculate the analytical sensitivity and specificity.
IFAT method
IFAT was employed as the reference method. Ready-to-use
slides bearing spots coated with P. falciparum antigen were
used. The antigen was prepared from A1 human red blood
cell cultures in vitro (Falciparum-Spot IF, bioMérieux,
Marcy l'Etoile, France). Sera were diluted 1/30 and 1/60 in
PBS before testing. Ten μL of each dilution were applied
to a spot, and the slides were incubated for 25 minutes at
37°C. One positive control and one negative control were
included in each series. The slides were washed twice forMalaria Journal 2007, 6:19 http://www.malariajournal.com/content/6/1/19
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10 minutes in PBS, then rinsed and dried before adding
fluorescein-labelled total human anti-Ig conjugate
(bioMérieux, Marcy l'Etoile, France) diluted at 1/200 in
PBS containing Evans blue (0.1 g/L). After incubation at
37°C for 25 minutes the slides were again washed twice
for 10 minutes in PBS, then rinsed and dried. The slides
were read under a fluorescence microscope (Zeiss) with
UV illumination and a × 40 objective. Samples fluorescing
at 1/30 dilution were considered equivocal, and samples
fluorescing at 1/60 dilution were considered positive fol-
lowing the in-house validated protocol [17-19].
ELISA malaria antibody test
The DiaMed ELISA malaria antibody test is based on bind-
ing of anti-Plasmodium antibodies present in a serum sam-
ple to antigens immobilized on 96-well plates. The
antigens are a mixture of a total extract of cultured P. fal-
ciparum and recombinant P. vivax antigens (MSP1 and
CSP). The test was done as recommended by the manufac-
turer, as follows. Ready-to-use diluent buffer (125 μL) was
dispensed into each well, followed by 25 μL of test serum.
On the same plate, 25 μL positive control and negative
control were also dispensed in single well and triplicate
wells respectively. The plate was then covered and incu-
bated for 60 minutes at 37°C before being washed 5
times. Horseradish peroxidase-conjugated rabbit anti-
human IgM and IgG monoclonal antibodies (100 μL)
were added to each well and the plates were incubated for
30 minutes at 37°C. The wells were again washed 5 times,
and 100 μL of substrate solution were added to each well.
The plate was covered and incubated in the dark for 15
minutes at 37°C. Finally, 50 μL of 0.5 M sulphuric acid
was added to each well and absorbance was read within
15 minutes at 450 nm, with a reference wave-length of
620 nm. The cut-off value was calculated by multiplying
the average optical density (OD) of the negative controls
wells by four (with a minimum value of 0.200). The anti-
body (Ab) index of each determination is obtained by
dividing the OD value of each sample by the cut-off value.
A negative reaction corresponds to an Ab index of 0.8 or
less, a positive reaction to an Ab index of 1.0 or more, and
an equivocal result to an Ab Index between 0.8 and 1.0.
The test does not distinguish between IgG and IgM, or
between antibodies to P. falciparum, P. vivax, P. ovale and
P. malariae.
This assay was carried out manually at the IPPTS, but was
adapted to automates for sample distribution (Genesis-
Tecan and Microlab AT 2+ from Hamilton) and micro-
plate managers (Ortho Summit Processor from Ortho
Clinical Diagnostics and BEP III from Dade Behring) at
EFS Alsace for the specificity study.
Investigations
All samples were tested using both IFAT and ELISA. IFAT,
for all samples, was performed at the IPPTS. ELISA, except
in the case of clinical samples, was performed at the EFS
Alsace.
Statistical analysis
Fisher's exact test was used to compare the performances
of the assays. Sensitivity, specificity, 95% confidence
interval (CI) and Youden's efficiency index (J) were calcu-
lated for both assays. Concordance and Cohen's Kappa
inter-rater reliability index (k) were also calculated
between the two tests. J and k indexes have a range from
0–1.00, with larger values indicating better efficiency and
reliability. Equivocal results for the same sera with both
assays were excluded from the calculations. Equivocal
results were considered as negative for sensitivity calcula-
tion, as positive for specificity calculation and for global
analysis. All equivocal cases are clearly identified in the
results section.
Results
Malaria-infected patients
In the samples from Plasmodium-infected patients, the
IFAT and ELISA sensitivity was 70.5% (67/95) and 84.2%
(80/95) respectively so not significantly different. Correla-
tion between the two methods was 0.76. More equivocal
results were observed with IFAT compared to ELISA (6
vs3). The mean and SD of ELISA ratios for the malaria-
infected group was 2.05 ± 1.6 (Table 1). These differences
may be may be explained by the detection of P. vivax
cases. Indeed, the performance of the IFAT and ELISA tests
varied according to the species (Table 2); the ELISA
method was three times more sensitive for P. vivax infec-
tion (24 cases, 75% for ELISA and 25% for IFAT). Both
tests failed to detect primary malarial infections. Consid-
ering the cases diagnosed in Strasbourg, IFAT and ELISA
both failed to detect three cases of P. falciparum from three
non-immune patients, considered as first-time tropical
travellers who had returned from West Africa less than
three months before (respectively three days, 10 days and
two weeks). For the nine P. vivax cases diagnosed at IPPTS,
three cases were not detected by ELISA and IFAT and three
by IFAT only. The three cases not detected by both ELISA
and IFAT were from first-time tropical travellers and P.
vivax  infection was microscopically diagnosed two
months, three months and 12 months after their return to
Europe. For the three remaining P. vivax cases, detected by
ELISA and not detected by IFAT, all were also from first-
time tropical travellers more three months after their
return from West Africa (four, five and 11 months). For
the 19 Venezuelan P. vivax cases, considered as residents,
three were missed by ELISA and IFAT, and nine by IFAT
only. Next, it was asked whether there are any differences
between first-time tropical travellers and multiple-timeMalaria Journal 2007, 6:19 http://www.malariajournal.com/content/6/1/19
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tropical travellers or patients resident in malarial areas for
malarial antibody detection. Clinical sensitivity perform-
ances are similar for both methods for primary-infected
patients compared to semi-immune patients (Table 3),
except for P. vivax cases, as previously stated. Concordance
for first-time travellers and frequent travellers were respec-
tively 0.81 and 0.84. Of note and not surprisingly, a posi-
tive serology was more often observed for frequent
travellers or malaria-area residents, as compared with pri-
mary infections.
Not-exposed-to-malaria blood donors
The clinical specificity for routine healthy non-exposed-
to-malaria blood donors (2152) was 99.6% for both
methods and raised concordance to 99.3% (Table 4). In
both methods, there were seven false positives but none
of them were concordant between the two methods, the
difference being not significant. The mean ELISA Ab index
for all the blood donors samples was 0.279 with an SD of
0.172 (median = 0.241), having in mind that the grey
zone starts at 0.800 and results are positive with a ratio
over or equal to 1.000. No other information was availa-
ble on the subjects presenting positive or equivocal results
for IFAT and/or ELISA. At that stage, the global clinical
performances of both methods, in Plasmodium-infected
patients and not-exposed-to-malaria blood donors, were
statistically similar (P = 0.331).
Malaria-risk blood donors
When tested, the 923 serum samples from healthy
malaria-risk blood donors (Table 5), four samples were
positive using both the IFAT and ELISA methods, and of
the 908 serum samples found negative by IFAT, 888 were
also negative by ELISA, with a ELISA Ab index mean and
SD of 0.380 ± 0.270. 31 ELISA false-positive results were
observed as compared to IFAT, the specificity falling to
96.8% (879/908). Among them 14 were equivocal for
ELISA and not confirmed by IFAT. However, it had previ-
ously been observed in the Plasmodium-infected patients
that the performance of ELISA was better for P. vivax cases,
and it was suggested that this may be due to the presence
of antibodies directed to P. vivax. Consequently, the 31
sera negative by IFAT and positive/equivocal by ELISA
were sent to the French National Reference Center for
Malaria (Prof. J. Le Bras, Laboratoire de Parasitologie,
Hôpital Bichat-Claude Bernard, Paris) for an IFAT using P.
cynomolgi antigens, the simian parasite P. cynomolgi from
rhesus monkeys being an alternative source of antigen for
serodiagnosis of P. vivax infection. All IFAT-P. cynomolgi
returned negative. Similarly, the ELISA analytical sensitiv-
ity was poor, falling to 40%, with a really poor 95% CI,
essentially due to sera equivocal for IFAT and negative for
ELISA.
Overall clinical performances
These showed an efficiency J index of 0.71 for IFAT and of
0.84 for ELISA, if the diagnosis of malaria is considered as
Table 1: ELISA and IFAT comparative results for Plasmodium infected patients
ELISA malaria antibody test
Positive Equivocal Negative Total
IFAT Positive 64 3 0 67
Equivocal 3036
Negative 13 0 9 22
Total 80 3 12 95
IFAT and ELISA clinical sensitivities respectively 70.5% (67/95) (CI: 59.6% – 81%) and 84.2% (80/95) (CI: 76.2% – 92.2%), equivocal results 
considered as negative for calculation.
Table 2: Positive results of ELISA and IFAT rates according to infecting Plasmodium species
Species (# cases; %) ELISA IFAT
P. falciparum (66 cases; 69.5%) 95.5%
63/66
95.5%
63/66
P. vivax (24 cases, 21%) 75%
18/24
25%
6/24
P. ovale (2 cases; 2.1%) 100%
2/2
100%
2/2
P. malariae (2 cases; 2.1%) 100%
2/2
100%
2/2
Mixed (1 case * ; 1%) 100%
1/1
100%
1/1
* P. falciparum plus P. malariaeMalaria Journal 2007, 6:19 http://www.malariajournal.com/content/6/1/19
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the reference (95 cases of microscopically diagnosed
malaria, irrespective of the species and 3075 cases of
healthy subjects without any clinical signs of malaria).
The comparison of the global performances of ELISA ver-
sus IFAT showed that the concordance was 0.97 and the
reliability k index 0.64 (Table 6).
Discussion and conclusion
Plasmodium infection triggers the synthesis of specific anti-
bodies, especially of the IgM and IgG isotypes (IgA levels
also rise, but to a lesser extent). Antibodies to all four Plas-
modium species are produced by virtually all individuals
1–14 days after infection [13,16]. Antibody titres decline
rapidly following recovery from primary infection, and
disappear within about a year. The presence of specific
antibodies is thus a marker of recent contact with Plasmo-
dium. Specific antibody titres are proportional to the
intensity and duration of infection, and serological meth-
ods are more sensitive than direct examination, when
used to assess past or present malaria infection, except in
the acute stage of the first infection, as the antibody titre is
independent of the date of infection and fluctuations in
blood parasite levels [2,3,20].
Serological methods have three main uses: a) screening in
transfusion centres located in non-endemic zones, with
large numbers of donors returning from endemic regions;
b) diagnosis of fever of unknown origin, especially in
patients inadequately treated for malaria and patients
with tropical splenomegaly: the mean antibody titre
reflects the intensity of contact with the parasite; and c)
epidemiological studies [11]. IFAT is considered as the
gold standard, but it is time consuming and lacks repro-
ducibility. Is a newly-established malaria ELISA antibody
test, combining native and recombinant-detecting anti-
gens, able to replace IFAT?
The ELISA performance in acute parasitaemic malaria
infection provides a way to measure its ability to detect
potential asymptomatic but parasitaemic patients. In the
Table 3: ELISA and IFAT results for first-time travellers (A) and frequent travellers or malaria area residents (B)
A ELISA malaria antibody Test
Positive Equivocal Negative Total
IFAT Positive 20 1 0 21
Equivocal 1012
Negative 3069
Total 2 4 173 2
IFAT and ELISA clinical sensitivities are respectively 65.6% (21/32) (CI: 45.3 – 85.9%) and 75% (24/32) (CI: 57.7 – 92.3%), equivocal results 
considered as negative for calculation.
B ELISA malaria antibody test
Positive Equivocal Negative Total
IFAT Positive 37 2 0 39
Equivocal 2024
Negative 1001
Total 4 0 224 4
IFAT and ELISA clinical sensitivities are respectively 88.6% (39/44) (CI: 78.7 – 98.6%) and 90.9% (40/44) (CI/82 – 99.8%), equivocal results 
considered as negative for calculation.
Table 4: ELISA and IFAT results for not-exposed-to-malaria blood donors
ELISA malaria antibody test
Positive Equivocal Negative Total
IFAT Positive 0044
Equivocal 0033
Negative 612 1 3 8 2145
Total 6 1 2145 2152
IFAT and ELISA clinical specificities: 99.6% (2145/2152) (CI: 99.4 – 99.9%), equivocal results considered as positive for calculation.Malaria Journal 2007, 6:19 http://www.malariajournal.com/content/6/1/19
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present study, the DiaMed ELISA malaria antibody test
had an overall sensitivity of 84.2% in patients with
malaria, compared to 70.5% with the IFAT method. Both
ELISA and IFAT methods still miss some cases of acute
infection, owing to the immunological window between
infection and antibody production, and to the high varia-
bility of Plasmodium  blood-stage antigens. Closing the
window by the use of antigen detection or PCR are under
investigation [21]. For P. falciparum cases, ELISA perform-
ances were similar to IFAT and markedly different for P.
vivax cases.
First generation ELISA kits, based exclusively on P. falci-
parum  antigens, showed a poor sensitivity for P. vivax
infection [22-24]. The relatively poor sensitivity of other
ELISA methods could be due to the use of soluble P. falci-
parum antigens without P. vivax antigens [13]. That point
reminds that serology remain very-species specific with a
substantial loss of titre when the right species is not used.
This is due to poor cross-reactivity among Plasmodium spe-
cies. The use of only one Plasmodium species for serologi-
cal diagnosis is theorically inadequate. The use of at least
three different antigens (P. falciparum, P. vivax, P. malar-
iae) should be used. Practically, since Trager and Jensen
continuous in vitro culture of P. falciparum discovery in
1976, only P. falciparum was used in laboratories. P. vivax
antigens are not available on an industrial scale, as P. vivax
cannot be cultured for long periods. The use of simian
parasite such as P. cynomolgi for P. vivax or P. brasilianum
for P. malariae is of limited use and is to be avoided for
large-scale use. The advent of recombinant technology has
allowed for diagnostic purposes the production of recom-
binant antigens from P. vivax. [25,26]. The performance of
an assay, using four recombinant antigens of P. falciparum
and P. vivax (The Newmarket Malarial Ab EIA from New-
market laboratories, Newmarket, England), as well as the
data presented here confirm that point [15,27]. Despite of
the low numbers of cases in both studies, these data
clearly suggest that the use of P. vivax recombinant anti-
gens in a malaria antibody ELISA increases the perform-
ance of the test in comparison with the P. falciparum IFAT
method.
However, no recombinant antigens from P. ovale and P.
malariae are available up to now. Therefore, the sensitivity
of the tests for P. ovale and P. malariae will probably be
poor with assays using only antigens from two Plasmo-
dium species. This is of importance especially for P. malar-
iae  infection, which is a frequent cause of transfusion
malaria. Therefore, the sensitivity of the DiaMed ELISA
malaria antibody test for P. ovale and P. malariae remains
to be determined, as these two species were rare in the
samples used here.
The DiaMed ELISA malaria test detects both malarial IgG
and IgM antibodies because IgM antibody can be detected
during malaria flare-ups and during both primary infec-
tion and re-infection, reflecting a response to new anti-
gens (first encounter with Plasmodium, or first encounter
with a new strain) [2,28]. The test uses also a crude P. fal-
Table 5: ELISA and IFAT results for malaria-risk blood donors
ELISA malaria antibody test
Positive Equivocal Negative Total
IFAT Positive 4004
Equivocal 20911
Negative 15 14 879 908
Total 21 14 888 923
ELISA analytical specificity and sensitivity are respectively 96.8% (879/908) (CI: 95.6 – 98%) and 40% (6/15) (CI: 0.8 – 79.2%) in comparison to IFAT, 
equivocal results considered as positive for calculation.
Table 6: ELISA and IFAT results for all subjects
ELISA malaria antibody test
Positive Equivocal Negative Total
IFAT Positive 68 3 4 75
Equivocal 501 5 20
Negative 34 15 3026 3075
Total 107 18 3045 3170
ELISA analytical sensitivity and specificity in comparison to IFAT are respectively 90.6% (68/75) (CI: 83.8 – 97.6%) and 98.7% (3056/3095) (CI: 98.3 
– 99.1%), equivocal results considered as negative.Malaria Journal 2007, 6:19 http://www.malariajournal.com/content/6/1/19
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ciparum  antigen preparation to improve sensitivity.
Indeed,  Plasmodium  epitopes are not uniformly recog-
nised by all patients. Frequently exposed subjects show
strong variability in their ability to mount a sustained
antibody response to a given antigen [28,29]. However,
use of anti-human IgM conjugates and of parasitic crude
antigen may in theory predispose the assay to false posi-
tive results, but we found a satisfactory 99.6% specificity
in non exposed to malaria blood donors.
Is ELISA able to replace IFAT in blood transfusion centres
where serological routine screening is used [21]? For the
moment, IFAT is still applied in Italy and Spain. If nega-
tive, donors are permitted to donate their blood [5]. In the
UK, Hong Kong, and recently in France, malaria antibody
ELISA is implemented, while it is under consideration in
Australia [3]. These countries are applying these screening
policies to detect malaria-risk donors, considering that
transfusion-transmitted malaria is rare in non-endemic
countries, with only three cases detected annually in the
USA [30]. However, many blood donations are wasted
because of the deferral or exclusion of donors who have
recently travelled to endemic areas. When the DiaMed
ELISA malaria antibody test kit was used to screen blood
donors on a large scale, the results agreed with those of the
IFAT reference method in 99.3% of cases of the not-
exposed-to-malaria blood donors and in 96.8% in
malaria-risk blood donors. The decreased specificity
observed in malaria-risk blood donors compared to the
not-exposed-to-malaria blood donors may be due to
either false positive results or detection of antibodies
directed to P. vivax antigens. Similar data were obtained
by others with malaria ELISA using recombinant antigens
[15]. However, the presence of P. vivax directed antibodies
by P. cynomolgi IFAT in our samples was not confirmed.
Numerous equivocal results were observed in the malaria
risk blood donors, 1.5% for ELISA and 1.1% for IFAT,
results considered in blood banks as positive following
the precautionary principle. None of these equivocal sam-
ples were concordant with both methods. All these dis-
cordant samples and obviously the positive ones too are
suspected to contain parasites. An Australian study was
unable to detect any plasmodial antigen or DNA in 337
malaria-risk blood donors, positive or negative by a New-
market malarial Ab ELISA, who had returned less than six
months or more than six months from a malaria-endemic
area [27]. In future, it would be of interest to investigate,
by similar methods, the presence of Plasmodium sp. in all
positive samples in the present study by ELISA and/or
IFAT.
In summary, the DiaMed ELISA-malaria antibody test
showed a better efficiency index than IFAT. That difference
is essentially due to the better performance of this ELISA
for the detection of P. vivax infected patients. The perform-
ance of this ELISA kit should also be extensively investi-
gated to check if the discrepancies in results between
ELISA and IFAT in samples from malaria-risk blood
donors are indeed true cases of infection, especially P.
vivax infections. A molecular approach is needed for that.
The better reactivity observed with south-American
patients and the 31 sera from donors with risk of malaria
that tested negative by IFAT, but positive or equivocal by
ELISA, may be due to cross reactivities with other proto-
zoan parasites (Leishmania, Trypanosoma, Toxoplasma)
[31]. An extensive expertise on sera from patients with
these pathologies should also be considered. Anyway,
overall efficiency and reliability of DiaMed ELISA malaria
antibody test make it an interesting candidate for the
replacement of IFAT in medical microbiology laboratories
and in blood banks, where the need for an ELISA method
that is easy to perform and suitable for automation is crit-
ical.
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